Preventing breast cancer resistance to CDK4/6 inhibitors using genomic findings

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in ...
pharmaphorum

Incyte breaks new ground in anal cancer with EU approval

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

'Superior memory' helps reprogrammed T cells hit tumors harder

A cancer drug class best known for attacking tumors may also help your immune system remember them better. Researchers at ...
News-Medical.Net on MSN

MSK uncovers how interacting mutations shield breast cancer

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs ...
Mirage News

Genomic Insights Tackle CDK4/6 Resistance in Breast Cancer

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients ...
The Manila Times

European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
Pharmabiz

Allarity closes $20 mn financing to accelerate the advance of stenoparib toward US FDA approval and commercialization

Tarpon Springs, Florida Monday, March 9, 2026, 15:00 Hrs [IST] ...

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and ...

The Prostate Cancer Foundation Provides $12 Million Through 2025 Challenge Awards to Accelerate Breakthroughs in Diagnosis and Treatment

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

Allarity Therapeutics, Inc.: Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured ...
Precision Medicine Online

EC Approves Akeega in BRCA-Mutated Hormone-Sensitive Prostate Cancer

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?

Pfizer PFE faces several near-term challenges like declining COVID sales, the upcoming loss of exclusivity (“LOE”) cliff and U.S. Medicare Part D headwinds. These headwinds can hurt its sales and ...